Viatris Inc. (VTRS)

♥ 330 Thanks from members

Viatris Inc. (VTRS) displays solid operational growth and raised 2026 financial guidance alongside major share buybacks, though its stock faced short-term downward pressure due to investor concerns over manufacturing disruptions at its Nashik facility and planned asset rights sales.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Health Care Industry: Pharmaceuticals Founder: Mylan and UpherSmith / Pfizer Upjohn Merger Leadership: Scott A. Smith (CEO) Holder: Vanguard Group Holder: BlackRock Inc. Holder: Wellington Management EpiPen Lipitor Norvasc Generic Pharmaceuticals #VTRS #Viatris #pharmaceuticals #generic drugs #NASDAQ VTRS